CpG island methylator phenotype in cancer
Top Cited Papers
- 1 December 2004
- journal article
- research article
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 4 (12) , 988-993
- https://doi.org/10.1038/nrc1507
Abstract
DNA hypermethylation in CpG-rich promoters is now recognized as a common feature of human neoplasia. However, the pathophysiology of hyper-methylation (why, when, where) remains obscure. Cancers can be classified according to their degree of methylation, and those cancers with high degrees of methylation (the CpG island methylator phenotype, or CIMP) represent a clinically and aetiologically distinct group that is characterized by 'epigenetic instability'. Furthermore, CIMP-associated cancers seem to have a distinct epidemiology, a distinct histology, distinct precursor lesions and distinct molecular features.Keywords
This publication has 45 references indexed in Scilit:
- Limitations of the Adenoma–Carcinoma Sequence in ColorectumClinical Cancer Research, 2004
- Epigenetics in human disease and prospects for epigenetic therapyNature, 2004
- The power and the promise of DNA methylation markersNature Reviews Cancer, 2003
- Unanswered Questions about the Role of Promoter Methylation in CarcinogenesisAnnals of the New York Academy of Sciences, 2003
- Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cellsOncogene, 2002
- DNA methylation patterns and epigenetic memoryGenes & Development, 2002
- Molecular Predictors of Survival after Adjuvant Chemotherapy for Colon CancerNew England Journal of Medicine, 2001
- Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinomaProceedings of the National Academy of Sciences, 1998
- Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colonNature Genetics, 1994
- Targeted mutation of the DNA methyltransferase gene results in embryonic lethalityPublished by Elsevier ,1992